Digital Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use, Clinical Practice, Therapeutic Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Digital Biomarkers Market size stood at USD 5.9 billion in 2026 and is predicted to grow at a 21.19% CAGR from 2027 to 2036, crossing USD 40.32 billion by 2036. The industry revenue for 2027 is calculated at USD 6.95 billion.
Get more details on this report
Request Free Sample ReportDigital Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 61.32% of the market in 2026, supported by its mature digital health ecosystem, rapid integration into clinical research, and widespread adoption of connected patient monitoring solutions.
- Asia Pacific is projected to grow at a 24.2% CAGR, driven by expanding digital health adoption, increasing use of connected devices, and broader implementation of remote patient monitoring across healthcare systems.
Segment Momentum
- Wearable devices captured a 41.98% share in 2026 because they enable continuous passive monitoring, providing consistent physiological and behavioral data for patient monitoring, research, and digital health applications.
- Payers are adopting digital biomarkers fastest because objective real-world health data helps improve outcome tracking, care management, coverage decisions, and healthcare utilization across insured populations.
Market Expansion Drivers
- Rapid adoption of wearables and smartphones enabling continuous real-time health data collection for digital biomarkers.
- Increasing use of decentralized clinical trials and remote monitoring accelerating digital biomarker integration in research.
- Expansion of AI-driven analytics improving interpretation of multimodal biometric data for disease prediction and monitoring.
Leading Market Participants
- Prominent players in the digital biomarkers market include AliveCor, Inc. (United States), Koneksa Health Inc. (United States), ActiGraph LLC (United States), Altoida, Inc. (United States), Empatica Inc. (United States), Huma Therapeutics Limited (United Kingdom), Clario (United States), Sonde Health, Inc. (United States), Kinsa Inc. (United States), Biogen Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.9 billion
- 2027 Estimated Market Size: USD 6.95 billion.
- Projected Market Size: USD 40.32 billion by 2036
- Growth Forecast: 21.19% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Wearable (Type) | Healthcare Companies (End-use) | Diagnostic Digital Biomarkers (Clinical Practice) | Cardiovascular and Metabolic Disorders (CVMD) (Therapeutic Area)
- Emerging Opportunity Segment: Mobile Based Applications (Type) | Payers (End-use) | Monitoring Digital Biomarkers (Clinical Practice) | Neurological Disorders (Therapeutic Area)
Market Growth Drivers and Industry Trends
Rapid adoption of wearables and smartphones enabling continuous real-time health data collection for digital biomarkers
The widespread adoption of connected wearables and smartphones is creating a stronger foundation for the digital biomarkers market by enabling health information to be captured continuously during routine daily activities. Smartwatches, fitness trackers, mobile applications, and other connected devices can generate physiological and behavioral data such as activity levels, sleep patterns, heart rate, and other measurable indicators. Unlike periodic assessments conducted in clinical environments, these technologies support longitudinal observation of individuals in real-world settings, increasing the availability and relevance of patient-generated data for disease monitoring, treatment assessment, and health research.
Increasing use of decentralized clinical trials and remote monitoring accelerating digital biomarker integration in research
The growing shift toward decentralized clinical trials and remote monitoring is expanding the role of digital measurements in research, with the digital biomarkers market benefiting from greater reliance on patient data collected outside traditional healthcare facilities. Remote technologies allow study participants to contribute information from their homes and everyday environments while reducing the need for repeated in-person assessments. Continuous access to physiological and behavioral observations can help researchers evaluate treatment responses, monitor changes in health status, and obtain a broader representation of patient experiences throughout clinical studies.
Expansion of AI-driven analytics improving interpretation of multimodal biometric data for disease prediction and monitoring
AI-driven analytics are becoming increasingly important for converting large volumes of digitally generated health information into clinically meaningful insights, strengthening the digital biomarkers market. Advanced algorithms can process multimodal biometric information from connected devices and identify relationships among physiological, behavioral, and activity-related signals that may be difficult to recognize through conventional analysis. These capabilities support the identification of patterns associated with disease progression, potential health risks, and treatment responses while helping healthcare and research professionals manage continuously generated datasets more effectively.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rapid adoption of wearables and smartphones enabling continuous real-time health data collection for digital biomarkers | 2.20% | High | North America, Europe | High | Near Term |
| Increasing use of decentralized clinical trials and remote monitoring accelerating digital biomarker integration in research | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Expansion of AI-driven analytics improving interpretation of multimodal biometric data for disease prediction and monitoring | 1.80% | Moderate | Europe, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the digital biomarkers market with a 61.32% share in 2026, supported by advanced digital health infrastructure, strong clinical research capabilities, and increasing integration of technology into patient monitoring and disease management. Healthcare providers and researchers are increasingly using digitally captured physiological, behavioral, and clinical data to support continuous monitoring, personalized treatment approaches, and more efficient clinical decision-making. Strong investment in healthcare innovation, widespread adoption of connected health technologies, and growing acceptance of data-driven care models continue to reinforce the region’s leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, driven by expanding digital healthcare infrastructure, increasing adoption of connected medical technologies, and rising demand for remote and personalized healthcare solutions. Greater use of smartphones, wearable devices, and digital monitoring tools is creating broader opportunities for biomarker collection outside conventional clinical settings. Healthcare modernization, expanding research activity, and growing interest in technology-enabled disease management are further supporting the adoption of digital biomarkers across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Evidence-Based IntegrationGermany is emphasizing clinically validated digital biomarkers that can be integrated into structured healthcare pathways and research programs. Market activity centers on demonstrating data reliability and improving disease monitoring through regulated digital health solutions.
France 🇫🇷
Clinical Research EnablementFrance is leveraging digital biomarkers to enhance clinical studies and patient monitoring programs, particularly in neurological and chronic conditions. Research institutions in France are increasingly evaluating digital endpoints that can complement conventional diagnostic methods.
Italy 🇮🇹
Telehealth Data AdoptionItaly is adopting digital biomarkers as telehealth services expand and healthcare providers seek more continuous patient data. Interest in Italy is centered on solutions that improve monitoring of chronic conditions and support care delivery beyond hospital settings.
Japan 🇯🇵
Aging Care AnalyticsJapan is prioritizing digital biomarkers to support remote monitoring and early detection of age-related conditions in its aging population. Healthcare organizations in Japan are exploring sensor-based technologies that enable continuous assessment outside traditional clinical settings.
South Korea 🇰🇷
Connected Health PlatformsSouth Korea is incorporating digital biomarkers into connected healthcare platforms that combine wearable devices, mobile applications, and hospital systems. The market is focused on improving patient engagement and generating actionable insights for chronic disease management.
United States 🇺🇸
Remote Monitoring EcosystemThe U.S. digital biomarkers market is advancing through strong adoption of wearable technologies and decentralized clinical trials. Healthcare providers and technology firms are investing in continuous patient monitoring solutions that generate real-world evidence for chronic disease management.
Segment Leadership and Growth Trends
Digital Biomarkers Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Wearable (Largest Segment) vs Mobile Based Applications (Fastest-Growing Segment)
Wearable devices held the largest share of the digital biomarkers market at 41.98% in 2026, supported by their ability to continuously capture physiological and behavioral information in real-world settings. Wearable technologies can monitor indicators such as activity, sleep patterns, heart rate, and other health-related signals, providing longitudinal data that can support patient monitoring and clinical research. Their growing integration into remote care, decentralized studies, and personalized health management strengthens their role as an important source of digital biomarker data.
Mobile based applications represent the fastest-growing type segment as smartphones provide a widely accessible platform for collecting behavioral, symptom, and patient-reported information. These applications can support frequent data capture without requiring dedicated hardware, making them suitable for remote monitoring, clinical research, and digital health programs. Increasing smartphone use, greater emphasis on patient engagement, and the expansion of software-enabled healthcare workflows are supporting stronger adoption of mobile-based digital biomarkers.
End-use Segment Analysis: Healthcare Companies (Largest Segment) vs Payers (Fastest-Growing Segment)
In the digital biomarkers market, healthcare companies represented the largest end-use segment in 2026, reflecting their need for continuous patient insights, treatment monitoring, and evidence generation. Digital biomarkers can help healthcare organizations supplement conventional clinical information with real-world physiological and behavioral data, supporting more informed care pathways and research activities. Growing adoption of remote monitoring and data-driven healthcare models continues to strengthen demand from this end-user group.
Payers are emerging as the fastest-growing end-use segment as reimbursement organizations increasingly seek objective data to support healthcare management, outcomes assessment, and value-based care initiatives. Digital biomarkers can provide additional insight into patient health status and treatment effectiveness outside conventional clinical encounters. Greater interest in remote care, preventive intervention, and evidence-based resource allocation is creating expanding opportunities for payer adoption.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Wearable, Mobile Based Applications, Sensors, Others | Wearable | Mobile Based Applications |
| End-use | Healthcare Companies, Healthcare Providers, Payers, Others | Healthcare Companies | Payers |
| Clinical Practice | Diagnostic Digital Biomarkers, Monitoring Digital Biomarkers, Predictive and Prognostic Digital Biomarkers, Others | Diagnostic Digital Biomarkers | Monitoring Digital Biomarkers |
| Therapeutic Area | Cardiovascular and Metabolic Disorders (CVMD), Respiratory Disorders, Psychiatric Disorders, Sleep & Movement Disease, Neurological Disorders, Musculoskeletal Disorders, Others | Cardiovascular and Metabolic Disorders (CVMD) | Neurological Disorders |
Competitive Landscape and Market Positioning
Leading companies in the digital biomarkers market:
1. AliveCor Inc. (United States)
2. Koneksa Health Inc. (United States)
3. ActiGraph LLC (United States)
4. Altoida Inc. (United States)
5. Empatica Inc. (United States)
6. Huma Therapeutics Limited (United Kingdom)
7. Clario (United States)
8. Sonde Health Inc. (United States)
9. Kinsa Inc. (United States)
10. Biogen Inc. (United States)
The digital biomarkers market is progressing through increased integration of real-time health monitoring systems and data-driven diagnostics. Analytical precision and patient-centric insights are becoming key development priorities. In the digital biomarkers market, digital health integration is transforming clinical decision-making frameworks.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| AliveCor Inc. (United States) | |||||||
| Koneksa Health Inc. (United States) | |||||||
| ActiGraph LLC (United States) | |||||||
| Altoida Inc. (United States) | |||||||
| Empatica Inc. (United States) | |||||||
| Huma Therapeutics Limited (United Kingdom) | |||||||
| Clario (United States) | |||||||
| Sonde Health Inc. (United States) | |||||||
| Kinsa Inc. (United States) | |||||||
| Biogen Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Dawn Health | Feb-26 | The company secured $13 million in funding to scale its AI-enabled digital disease management platform. This investment will support the enhancement of advanced analytics capabilities and the expansion of connected health solutions, significantly strengthening the company’s infrastructure for large-scale digital biomarker deployment and real-time patient monitoring. |
| AiZtech Labs | Feb-26 | The company launched iSelfie BioSignals in the U.S. market, a novel smartphone-based digital biomarker platform. Utilizing advanced Vision AI, the solution automates critical patient intake and triage processes while facilitating biomarker detection, representing a strategic effort to improve clinical accessibility and operational efficiency in patient monitoring. |
| Global Alzheimer’s Platform Foundation | Feb-26 | The Global Alzheimer’s Platform Foundation (GAP) entered a strategic partnership with Spear Bio for the Bio-Hermes-002 study. This initiative aims to accelerate the development and validation of digital and molecular biomarker-based diagnostic pathways for Alzheimer’s disease and related dementias, addressing a critical need for objective detection methods in neurodegenerative disease research. |
| electronRx | Feb-26 | The company launched its pDx mobile application, designed to facilitate remote lung-function monitoring and the collection of digital biomarkers for chronic respiratory disease management. This launch expands the company's clinical footprint, providing a scalable digital solution for longitudinal health tracking and data-driven management of complex respiratory conditions. |
| Neuron23 | Feb-26 | Neuron23 expanded its precision medicine initiatives in Parkinson’s disease through strategic partnerships aimed at incorporating fit-for-purpose digital biomarker solutions into its clinical development programs. This move indicates a focus on leveraging objective, real-world data to refine patient stratification and therapeutic efficacy assessment in neurodegenerative clinical trials. |
| GrayMatters Health | Feb-26 | The company published new clinical research validating its fMRI-informed digital brain biomarkers for mental health management. This validation strengthens the clinical utility and regulatory profile of its technology, providing a clear pathway for integrating specialized neural biomarkers into standardized care and diagnostic workflows. |
| Quibim | Feb-26 | Quibim appointed a new Chief Business Officer to accelerate the commercialization of its AI-powered imaging biomarker solutions. This strategic leadership move is intended to strengthen the company’s market penetration within the pharmaceutical and precision medicine sectors, focusing on expanding the clinical adoption of its imaging-based digital diagnostic platforms. |
| Biogen | Feb-26 | Biogen reported notable progress in implementing digital innovation strategies to optimize clinical trial operations. By deploying advanced digital monitoring technologies to enhance patient access and trial participation, the company is setting a framework for improving the quality and consistency of data collection in complex clinical development programs. |
| Regeneron | Jan-26 | Regeneron partnered with Koneksa to integrate digital biomarkers into Parkinson’s disease clinical trials. This collaboration underscores a strategic shift toward utilizing objective, sensor-based digital measures to improve disease monitoring and optimize trial endpoints, reflecting growing industry reliance on digital health data for precision therapeutic development. |
| Novartis | Jan-26 | Novartis reported significant advancements in deploying digital biomarkers for knee osteoarthritis clinical trials. By leveraging specialized digital health technologies to improve patient assessment, the company is demonstrating the tangible value of objective digital metrics in enhancing trial outcomes and increasing the precision of longitudinal disease monitoring. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Digital Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Pricing Model | Subscription-Based, Per-Patient Licensing, Per-Study/Project-Based, Usage-Based |
| Regulatory Status | Regulatory-Cleared, Regulatory-Approved, Research-Use Only |
| Integration Approach | Standalone Platforms, Electronic Health Record Integrated, Clinical Trial Integrated, Remote Patient Monitoring Integrated |
Digital Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathway Assessment |
|
| Digital Biomarker Data Ecosystem Analysis |
|
| Remote Monitoring Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of digital biomarkers?
How is the digital biomarkers industry projected to perform over the next decade?
How are wearable devices and smartphones transforming data collection in the digital biomarkers market?
How is decentralized clinical research influencing adoption of digital biomarkers?
Why are wearable devices the largest type segment in the digital biomarkers market?
Why are payers the fastest-growing end-use segment in the digital biomarkers market?
Why is North America the leading digital biomarkers market?
What is accelerating digital biomarkers market growth in Asia Pacific?
Which organizations are considered leaders in the digital biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization